<DOC>
	<DOCNO>NCT01342497</DOCNO>
	<brief_summary>The aim Clinical Proof Principle study evaluate effect BBR-012 healing complicate diabetic foot ulcer .</brief_summary>
	<brief_title>Oral BBR-012 Treatment Diabetic Foot Ulcers , Proof Concept Study</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Main Aged ≥18 Diabetes mellitus Ischaemic neuroischaemic Diabetic Foot Ulcer malleolus , wholly sole foot ( minimum size : 1 cm x 1 cm ) Body Mass Index ( BMI ) ≤40 kg/m2 Women childbearing potential must use acceptable method birth control Written inform consent participate study Patients must able speak English fluently understand English Main Any uncontrolled illness ( e.g . active malignancy , vasculitis ) , opinion investigator , would interfere interpret result study Infected Diabetic Foot Ulcer base IDSA guideline , i.e . presence purulent secretion least two manifestation inflammation ( erythema , warmth , swell induration pain tenderness ) , , investigator 's judgment , intravenous oral antibiotic therapy require Active osteomyelitis Wholly plantar Diabetic Foot Ulcer Suspected gangrenous tissue affect limb remove single debridement Diabetic Foot Ulcer associate prosthetic material device Received potentially effective systemic antibiotic therapy 24 hour 72hour period screen visit Is receive , receive within 14 day prior screen visit , concomitant topical wound therapy ( e.g. , topical antimicrobial therapy , topical debriding agent , topical growth factor , topical skin replacement , hyperbaric oxygen ) Has receive systemic corticosteroid , immunosuppressive agent , radiation therapy chemotherapy within 30 day prior screen visit . Hepatic impairment , renal impairment ( define estimate glomerular filtration rate &lt; 10 mL/minute/1.73m2 ) , hypersensitivity isoniazid . High risk tuberculosis , e.g . HIV positive , immunosuppressed , active malignancy Symptoms active latent tuberculosis ( base specific history , physical examination , Interferon Gamma Release Assay ( IGRA ) test chest XRay ) Known suspect drug alcohol abuse positive drug abuse test . Participating clinical study 12 week screen visit Donation 450 mL blood 3 month screen visit , 1200 mL blood 12 month screen visit . History severe hypersensitivity ongoing hypersensitivity might affect patient 's suitability study ( e.g . hypersensitivity wound dressing ) , judge investigator . History allergy , insensitivity , local anaesthetic Use prescribe nonprescribed ( overthecounter ) medication , include herbal medication ( e.g. , St. Johns Wort ) could possibly interfere objective study ( e.g. , could affect closure chronic dermal ulceration ) , 2 week ( 5 halflives compound whichever long ) anticipate first dose study medication . Occasional paracetamol pain relief ( maximum 2 g per 24 hour ) adrenergic nasal spray relief nasal congestion allow Having receive BBR012 isoniazid within 6 month prior screen visit Bleeding disorder history increase bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>diabetic foot ulcer</keyword>
</DOC>